US Patent

US12263153 — Pharmaceutical composition, methods for treating and uses thereof

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2034-04-03 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease using empagliflozin.

USPTO Abstract

The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4171 — Jardiance
U-4154 — Jardiance
U-4154 — Jardiance
U-4154 — Jardiance
U-4154 — Jardiance
U-4154 — Jardiance
U-4154 — Jardiance
U-4154 — Jardiance
U-4154 — Jardiance
U-4171 — Jardiance

Patent Metadata

Patent number
US12263153
Jurisdiction
US
Classification
Method of Use
Expires
2034-04-03
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.